Falls and Functional Impairments in Breast Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy

Hiroko Komatsu; Kaori Yagasaki; Yasuhiro Komatsu; Hideko Yamauchi; Teruo Yamauchi; Toshio Shimokawa; Ardith Z Doorenbos

doi:10.4103/apjon.apjon_7_19

Users Online: 684

ORIGINAL ARTICLE

Year : 2019 | Volume : 6 | Issue : 3 | Page : 253-260

Falls and Functional Impairments in Breast Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy

Hiroko Komatsu¹, Kaori Yagasaki¹, Yasuhiro Komatsu², Hideko Yamauchi³, Teruo Yamauchi⁴, Toshio Shimokawa⁵, Ardith Z Doorenbos⁶
¹ Faculty of Nursing and Medical Care, Keio University, Tokyo, Japan
² Department of Healthcare Quality and Safety, Gunma University Graduate School of Medicine, Gunma, Tokyo, Japan
³ Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan
⁴ Division of Medical Oncology, St. Luke's International Hospital, Tokyo, Japan
⁵ Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, Wakayama, Japan
⁶ Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago, Chicago, IL; Department of Biobehavioral Health Science, College of Nursing, University of Illinois at Chicago and Department of Biobehavioral Nursing and Health Informatics, School of Nursing, University of Washington, WA, USA

Correspondence Address:
Hiroko Komatsu
Faculty of Nursing and Medical Care, Keio University, Tokyo
Japan

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/apjon.apjon_7_19

Objective: We investigated the incidence of falls and functional impairments in breast cancer patients with chemotherapy-induced peripheral neuropathy (CIPN). Additionally, we examined whether taxane-induced peripheral neuropathy was associated with the patients' falls and functional impairments. Methods: We conducted a cross-sectional study including 88 patients with breast cancer who received taxane-based chemotherapy and were recognized as having peripheral neuropathy symptoms (Common Terminology Criteria for Adverse Events Grade ≥1). Patients completed the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity questionnaire for neuropathy and described falls from the onset of the taxane-based chemotherapy to the time of the survey. Functional impairments were defined using the Activities of Daily Living subsection of the Vulnerable Elder's Scale. Data were analyzed using descriptive statistics and logistic regression. Results: Of the participants, 40.9% experienced falls and 38.4% reported functional impairments. Most falls occurred on flat ground. Bone fracture due to falls was observed in 11.4% of the participants. Logistic regression revealed that CIPN was not significantly associated with the reported incidence of falls. However, it was significantly associated with functional impairments (odds ratio, 6.415; 95% confidence interval: 1.271–32.379; P = 0.024). Conclusions: CIPN was associated with functional impairments, but not with the incidence of falls. Patients should be informed prior to the onset of anticancer therapy that CIPN is a risk factor for functional impairments.

[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics
Viewed	1843
Printed	120
Emailed	0
PDF Downloaded	247
Comments	[Add]
Cited by others	4